Skip to main content

Table 1 Clinical characteristics of the IPF patients

From: Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients

Clinical characteristics

Patients (n = 25)

Progressive disease (n = 9)

Non-progressive disease (n = 15)

p values

Age (years, mean ± SD)

69 ± 8

67 ± 9

70 ± 8

NS

Gender

 Male % (n)

68 (17)

67 (6)

67 (10)

NS

 Female % (n)

32 (8)

33 (3)

33 (5)

NS

Tabagism

 Non-smoker % (n)

12 (3)

11 (1)

13 (2)

NS

 Active smokers % (n)

0 (0)

0 (0)

0

NS

 past smokers % (n)

80 (20)

78 (7)

80 (12)

NS

 Passive smoker % (n)

8 (2)

11 (1)

7 (1)

NS

Anti-fibrotic treatment

 Pirfénidone % (n)

56 (14)

67 (6)

46 (7)

NS

 Nintedanib % (n)

44 (11)

33 (3)

54 (8)

NS

Pulmonary function tests

FVC (l, mean +/− SD)

2,4 ± 0,8

2,2 ± 0,8

2,5 ± 0,7

NS

FVC (%, mean +/− SD

73,7 ± 20,2

63,6 ± 17,2

78,9 ± 20,6

NS

DLCO (ml/min/mmHg, mean +/− SD)

10,5 ± 3,5

9,3 ± 3,4

11,1 ± 3,4

NS

DLCO (%, mean +/− SD)

43,5 ± 12,0

38,3 ± 11,3

46,8 ± 11,5

NS

GAP score (n):

 Stage 1% (n)

28 (7)

11 (1)

40 (6)

NS

 Stage 2% (n)

56 (14)

67 (6)

47 (7)

NS

 Stage 3% (n)

16 (4)

22 (2)

13 (2)

NS

  1. For 24 patients, a follow up was available to classify them as having a progressive or non-progressive disease (middle and right column respectively). NS = not significant (p < 0.05)